These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

71 related articles for article (PubMed ID: 23121011)

  • 1. TP53 mutation is rare in primary myelofibrosis.
    Greaves WO; Verma S; Bisrat T; Strati P; Rahimi H; Paladugu AV; Luthra R; Patel KP; Medeiros LJ; Yao H; Pierce S; Bueso-Ramos CE; Verstovsek S
    Leuk Lymphoma; 2013 Jul; 54(7):1552. PubMed ID: 23121011
    [No Abstract]   [Full Text] [Related]  

  • 2. TP53 mutations and polymorphisms in primary myelofibrosis.
    Raza S; Viswanatha D; Frederick L; Lasho T; Finke C; Knudson R; Ketterling R; Pardanani A; Tefferi A
    Am J Hematol; 2012 Feb; 87(2):204-6. PubMed ID: 22052707
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prognostic significance of ASXL1 mutation types and allele burden in myelofibrosis.
    Tefferi A; Lasho TL; Finke C; Gangat N; Hanson CA; Ketterling RP; Pardanani A
    Leukemia; 2018 Mar; 32(3):837-839. PubMed ID: 29089644
    [No Abstract]   [Full Text] [Related]  

  • 4. Clinical and molecular genetic characterization of myelofibrosis.
    Hobbs GS; Rampal RK
    Curr Opin Hematol; 2015 Mar; 22(2):177-83. PubMed ID: 25635755
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Molecular correlates of anemia in primary myelofibrosis: a significant and independent association with U2AF1 mutations.
    Barraco D; Elala YC; Lasho TL; Begna KH; Gangat N; Finke C; Hanson CA; Ketterling RP; Pardanani A; Tefferi A
    Blood Cancer J; 2016 Apr; 6(4):e415. PubMed ID: 27058230
    [No Abstract]   [Full Text] [Related]  

  • 6. An unusual long-term outcome of a child with primary myelofibrosis harboring a JAK2 mutation.
    Maia RC; Bonamino MH; Robaina MC; Amaral N; Bonecker S; Zalcberg IR; Klumb CE
    Blood Cells Mol Dis; 2015 Dec; 55(4):347-50. PubMed ID: 26460258
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Co-existence of JAK2 V617F and CALR mutations in primary myelofibrosis.
    Zamora L; Xicoy B; Cabezón M; Fernandez C; Marcé S; Velez P; Xandri M; Gallardo D; Millá F; Feliu E; Boqué C
    Leuk Lymphoma; 2015; 56(10):2973-4. PubMed ID: 25686645
    [No Abstract]   [Full Text] [Related]  

  • 8. Prognosis and survivorship in primary myelofibrosis.
    Reilly JT
    Am J Hematol; 2010 Jan; 85(1):4-5. PubMed ID: 20029947
    [No Abstract]   [Full Text] [Related]  

  • 9. The lack of association between JAK2 V617F mutation and myelodysplastic syndrome with or without myelofibrosis.
    Yip SF; So CC; Chan AY; Liu HY; Wan TsK; Chan LC
    Leukemia; 2006 Jun; 20(6):1165. PubMed ID: 16572200
    [No Abstract]   [Full Text] [Related]  

  • 10. CALR mutation, MPL mutation and triple negativity identify patients with the lowest vascular risk in primary myelofibrosis.
    Finazzi MC; Carobbio A; Cervantes F; Isola IM; Vannucchi AM; Guglielmelli P; Rambaldi A; Finazzi G; Barosi G; Barbui T
    Leukemia; 2015 May; 29(5):1209-10. PubMed ID: 25482134
    [No Abstract]   [Full Text] [Related]  

  • 11. CALR-mutated primary myelofibrosis evolving to chronic myeloid leukemia with both CALR mutation and BCR-ABL1 fusion gene.
    Diamond JM; de Almeida AM; Belo HJ; da Costa MP; Cabeçadas JM; Abecasis MM
    Ann Hematol; 2016 Dec; 95(12):2101-2104. PubMed ID: 27699446
    [No Abstract]   [Full Text] [Related]  

  • 12. The impact of cytogenetic abnormalities on the prognosis of primary myelofibrosis: a prospective survey of 202 cases in Japan.
    Hidaka T; Shide K; Shimoda H; Kameda T; Toyama K; Katayose K; Kubuki Y; Nagata K; Takenaka K; Akashi K; Okamura T; Niho Y; Mizoguchi H; Omine M; Ozawa K; Harada M; Shimoda K
    Eur J Haematol; 2009 Oct; 83(4):328-33. PubMed ID: 19549278
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prognostic relevance of cytogenetic abnormalities in primary myelofibrosis: comparison of recent reports from Japan, the Mayo Clinic and MD Anderson Cancer Center.
    Tefferi A
    Eur J Haematol; 2009 Oct; 83(4):290-1. PubMed ID: 19558507
    [No Abstract]   [Full Text] [Related]  

  • 14. The first report of chronic myelogenous leukemia with e19a2 micro-BCR/ABL1 presenting with massive myelofibrosis.
    Kim HY; Park S; Kim SH; Kim HJ
    Blood Cells Mol Dis; 2017 Jun; 65():68-70. PubMed ID: 28571780
    [No Abstract]   [Full Text] [Related]  

  • 15. Prognosis of Primary Myelofibrosis in the Genomic Era.
    Bose P; Verstovsek S
    Clin Lymphoma Myeloma Leuk; 2016 Aug; 16 Suppl():S105-13. PubMed ID: 27521306
    [TBL] [Abstract][Full Text] [Related]  

  • 16. MPL mutations and palpable splenomegaly are independent risk factors for fibrotic progression in essential thrombocythemia.
    Haider M; Elala YC; Gangat N; Hanson CA; Tefferi A
    Blood Cancer J; 2016 Oct; 6(10):e487. PubMed ID: 27768091
    [No Abstract]   [Full Text] [Related]  

  • 17. Improved survival in patients with CALR1 compared to CALR2 mutated primary myelofibrosis: a meta-analysis.
    Kourie HR; Ameye L; Paesmans M; Bron D
    Br J Haematol; 2017 Dec; 179(5):846-848. PubMed ID: 27434541
    [No Abstract]   [Full Text] [Related]  

  • 18. Systemic Inflammation and Myelofibrosis in a Patient with Takenouchi-Kosaki Syndrome due to CDC42 Tyr64Cys Mutation.
    Bucciol G; Pillay B; Casas-Martin J; Delafontaine S; Proesmans M; Lorent N; Coolen J; Tousseyn T; Bossuyt X; Ma CS; Schrijvers R; Tangye SG; Moens L; Meyts I
    J Clin Immunol; 2020 May; 40(4):567-570. PubMed ID: 31953712
    [No Abstract]   [Full Text] [Related]  

  • 19. [Splanchnic vein thrombosis as a first manifestation of Primary myelofibrosis].
    Campos-Cabrera G; Campos-Cabrera V; Campos-Cabrera S; Campos-Villagómez JL; Romero-González A
    Gac Med Mex; 2017; 153(4):537-540. PubMed ID: 28991281
    [TBL] [Abstract][Full Text] [Related]  

  • 20. MIPSS70+ Version 2.0: Mutation and Karyotype-Enhanced International Prognostic Scoring System for Primary Myelofibrosis.
    Tefferi A; Guglielmelli P; Lasho TL; Gangat N; Ketterling RP; Pardanani A; Vannucchi AM
    J Clin Oncol; 2018 Jun; 36(17):1769-1770. PubMed ID: 29708808
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 4.